AHR and prostate carcinoma: Additionally, the switch in transcription factors from androgen receptor (AR) to glucocorticoid receptor (GR) modulated the persistent expression of TDO2, and the same TDO2-Kyn-AhR signalling pathway promoted the aggressive proliferation of prostate cancer cells in the ADT-resistant cell stage.